Nimotuzumab is currently being advanced in several randomized Phase II and III trials in Japan, Europe and elsewhere and is undergoing an YM-sponsored confirmatory trial in pediatric glioma
This newly issued patent describes a method of determining the presence of neural injury through the measurement of proteolytic breakdown products of microtubule-associated proteins (MAP). The company has
The realignment will result in the elimination of a number of positions and additional refinement to Elan’s commercial activities in Tysabri for Crohn’s disease. Elan has also decided
Both patents are associated with emtricitabine, a component of Truvada and are licensed exclusively to Gilead Sciences by Emory University. Truvada is indicated in combination with other antiretroviral
Momenta estimates that net proceeds from the offering will be approximately $24.1 million, after deducting placement agent fees and estimated offering expenses. Momenta currently intends to use the
Under the terms of the agreement, all pending disputes between the companies will be immediately dismissed. In addition, the companies have agreed to cross license certain patents. The
Aetna will collaborate with Gateway Healthcare to provide administrative and financial services to outpatient care practices (OCPs) in Dubai. The two companies will also offer management services like
In the preliminary analysis, 18% of patients (n=23) given a regimen of Abraxane (nab-paclitaxel), gemcitabine and epirubicin achieved a complete pathologic response and 68% (n=84) achieved a partial
Pfizer laid the blame on the rising R&D costs, increasing generic competition and tougher drug regulations for its restructuring operations in France. The global pharmaceutical industry has seen
The advisory committee voted 15-0 that the product is approvable with the condition that the FC2 Female Condom’s instructions for use continue to follow use instructions for the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.